[go: up one dir, main page]

WO1991010434A1 - Medicaments comprenant de la methylcellulose ou de l'hydroxyalkyle methylcellulose, et leur utilisation - Google Patents

Medicaments comprenant de la methylcellulose ou de l'hydroxyalkyle methylcellulose, et leur utilisation Download PDF

Info

Publication number
WO1991010434A1
WO1991010434A1 PCT/GB1991/000018 GB9100018W WO9110434A1 WO 1991010434 A1 WO1991010434 A1 WO 1991010434A1 GB 9100018 W GB9100018 W GB 9100018W WO 9110434 A1 WO9110434 A1 WO 9110434A1
Authority
WO
WIPO (PCT)
Prior art keywords
methylcellulose
medicament
powder
hydroxyalkyl
allergies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1991/000018
Other languages
English (en)
Inventor
Michael Henry James
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MUTRACT Ltd
Original Assignee
MUTRACT Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MUTRACT Ltd filed Critical MUTRACT Ltd
Publication of WO1991010434A1 publication Critical patent/WO1991010434A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Definitions

  • a medicament comprising methylcellulose or hydroxyalkyl methylcellulose, and use thereof.
  • This invention relates to medicaments for therapeutic treatments, such as treatments for protecting sensitized nerve endings from over stimulation, and is more particularly, but not exclusively, concerned with treatment of allergies and other conditions caused by inhalation of airborne irritants. Many people suffer to a greater or lesser extent from the effects of allergies due to inhalation of airborne irritants, such as pollen or household dust.
  • hay fever Allergic Rhinitis
  • Known methods of treatment of hay fever are not always reliable and can give rise to undesirable side effects, such as drowsiness.
  • a medicament comprising methylcellulose or hydroxyalkyl methylcellulose for use as an active ingredient in a therapeutic method.
  • a medicament comprising methylcellulose or hydroxyalkyl methylcellulose for use in the treatment by nasal administration of allergies and other conditions caused by inhalation of airborne irritants.
  • methylcellulose or hydroxyalkyl methylcellulose for the preparation of a medicament for use as an active ingredient in a therapeutic method involving protecting sensitized nerve endings from over stimulation.
  • methylcellulose or hydroxyalkyl methylcellulose for the preparation of a medicament for use in the treatment by nasal administration of allergies and other conditions caused by inhalation of airborne irritants.
  • the methylcellulose or hydroxyalkyl methylcellulose may be in powder, liquid or gel form, and may be in the form of hydroxypropyl methylcellulose, hydroxyethyl methylcellulose, hydroxymethyl methylcellulose or hydroxybutyl methylcellulose.
  • the powder has effective particle sizes acceptable to the nose and preferably less than about 50 microns diameter (or about 25 microns diameter in some circumstances) .
  • the powder will consist of particles having effective particle diameters in the range of about 5 to about 50 microns, and preferably in the range of about 10 to about 40 microns.
  • hydroxypropyl methylcellulose as a thickener and suspending agent in the pharmaceutical and food industries is well known. It is also used as a tablet binder and in ophthalmic preparations (see Martindale, The Extra Pharmacopeia, 28th Edition, page 956) .
  • this substance has been no previous suggestion to use this substance as the therapeutic component of a medicament for use in desensitizing over-sensitized nerve endings, or more specifically in the treatment by nasal administration of allergies and other conditions caused by inhalation of airborne irritants.
  • the medicament of the invention is capable of broad application to humans or animals in the treatment of respiratory problems, including pneumoconiosis and asthma, as well as in other applications in which sensitized nerve endings are to be protected from over stimulation. In certain of these applications it may be appropriate for the medicament to be orally inhaled or swallowed, or for the medicament to be in the form of a gel.
  • the invention also provides a delivery system for a medicament for use as an active ingredient in a therapeutic method, the system comprising a container for the medicament, sealing means for closing off the container, and open cell foam means within the container for holding medicament in such a manner as to enable a quantity of the medicament held within the foam means to be inhaled through the user's nose or otherwise administered to the user.
  • the container is a flexible strip having a pocket containing the foam means and having an opening to the pocket in one face, and the sealing means is a piece of adhesive tape which closes off the opening.
  • the container is a receptacle having a top and having a pad of foam means at its top so that the foam means may be charged with medicament by turning the receptacle upside down
  • the sealing means is a detachable cap which closes off the top of the receptacle including the foam means.
  • the receptacle preferably has flexible walls so as to permit the receptacle to be squeezed to assist inhalation of medicament.
  • Figure l is a schematic view of a delivery system for the medicament in accordance with the invention.
  • FIG. 2 is a section through an alternative delivery system for the medicament in accordance with the invention.
  • hydroxypropyl methylcellulose powder is taken by the user in the manner of snuff.
  • the hydroxypropyl methylcellulose powder is produced from the cellulose fibres of cotton linters or wood pulp with hydroxypropyl substitution on the anhydroglucose unit being introduced during manufacture.
  • An appropriate powder is that sold under the Registered Trade Mark, Methocel. Such a powder conforms to U.S.P., Food Chemicals Codex, Kosher Certification and F.D.A. regulations.
  • hydroxypropyl methylcellulose powder Whilst various grades of hydroxypropyl methylcellulose powder may be used, it is much preferred that a grade of powder should be used which has a nominal viscosity in a 2% aqueous solution close to that of mucus, and typically in a range of 4000 to 100000 cP at 20° C (although it is preferable that this value is greater than 6000, and most preferably greater than 8000, and/or that this value is less than 50000, and most preferably less than 30000) .
  • the powder should also have a high hydration rate so that it will form a gel in a short period of time, typically 3 to 5 seconds, on contact with warm, damp air.
  • a preferred grade of Methocel powder is that sold as K15M Premium which has a nominal viscosity of 15000 cP in 2% aqueous solution at 20° C.
  • the powder When inhaled the powder acts as a "chemical bandage" to protect sensitized nerve endings within the nose or throat from over stimulation by inhaled irritants. It does this because the powder turns to a gel on contact with the moisture naturally present in the nasal passages. This gently protects the disturbed nerve endings long enough for them to return to their normal sensitivity.
  • the powder disperses after a while, and is absorbed by the body without any adverse affect. Under most conditions it should not be necessary to administer the powder more than once or twice a day.
  • the powder can be used as a carrier for carrying any suitable drug, for use in treatment of asthma, for example, to the respiratory tract, or elsewhere in the body, and for holding the drug in the required location.
  • the powder can be taken simply in the manner of snuff without requiring a special delivery system, it is preferred that the powder is applied and administered by a special delivery system which ensures that the correct amount of powder is taken in a particularly reliable manner.
  • Figure 1 shows a delivery system 1 in the form of a flexible and transparent plastics strip 2 formed by heat welding together two plastics sheets along weld lines 3, 4 and 5 so as to form a pocket 6 for a pad 7 of open cell foam containing the powder.
  • a circular opening 8 is provided in one of the plastics sheets to provide access to the pocket 6, and this opening 8 is closed off by a piece 9 of adhesive tape (shown in broken lines) applied to one face of the strip 2 when the delivery system 1 is supplied for use.
  • the piece 9 of adhesive tape is removed so as to provide access to the powder in the foam pad 7 by way of the opening 8 to permit the powder to be delivered to the user's nose or mouth.
  • the strip 2 is then held by the user grasping each end of the strip 2 between the thumb and forefinger of each hand, and positioned so that the opening 8 is immediately beneath one nostril.
  • the required amount of powder is then taken up by a gentle sniff, and the procedure is repeated for the other nostril.
  • the delivery system 1 is then disposed of.
  • Figure 2 shows an alternative delivery system 10 in which a quantity of powder 11 sufficient for a number of doses is held within a tubular receptacle 12 made of flexible plastics material.
  • the receptacle 12 is formed at its top with a first screwthread 13 for receiving a detachable screwthreaded cap 14, and a second screwthread 15 for receiving a screwthreaded foam pad holder 16.
  • the pad holder 16 comprises a screwthreaded collar 17, an open cell foam pad 18 and an apertured domed member 19.
  • the form of the apertures in the domed member 19 is shown in the view from below of the member 19 at (a) in Figure 2.
  • the foam pad 18 is held at its periphery between an outer circular flange 20 of the domed member 19 and an inner circular flange 21 of the collar 17. Furthermore the flange 20 of the domed member 19 is trapped in position when the collar 17 is held in screwthreaded engagement with the top of the receptacle 12.
  • the receptacle 12 is turned upside down to charge the foam pad 18 with powder.
  • the receptacle 12 is then turned upright and the cap 14 is removed by unscrewing it from the receptacle 12.
  • the user has gently blown his nose, he then places the foam pad 18 on top of the receptacle 12 immediately below one nostril and lightly sniffs the pad 18 so as to inhale the powder, whilst squeezing the walls of the flexible receptacle 12.
  • the procedure is then repeated for the second nostril, and the cap 14 is subsequently replaced, the receptacle 12 being stored for further use.
  • the medicament can also be used as a "chemical bandage" in other applications within the scope of the invention.
  • the medicament may be applied in the form of a powder or liquid to tissue during surgery so that it will form a "chemical bandage” preventing undesirable cohesion of tissue after surgery.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La cellulose de méthyle ou la cellulose de méthyle hydroxyalkyle est utilisée dans un procédé thérapeuthique impliquant la protection des terminaisons nerveuses sensibilisées par un excès de stimulation et, en particulier dans le traitement par administration nasale des allergies et autres états provoqués par l'inhalation de substances irritantes transportées par l'air. La médication forme un gel protégeant les terminaisons nerveuses perturbées pendant un laps de temps assez long pour qu'elles retrouvent leur sensibilité normale. L'action de la médication est rapide et directe et n'a pas d'effets secondaires.
PCT/GB1991/000018 1990-01-09 1991-01-07 Medicaments comprenant de la methylcellulose ou de l'hydroxyalkyle methylcellulose, et leur utilisation Ceased WO1991010434A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909000459A GB9000459D0 (en) 1990-01-09 1990-01-09 Medicaments for treatment of airborne allergies
GB9000459.9 1990-01-09

Publications (1)

Publication Number Publication Date
WO1991010434A1 true WO1991010434A1 (fr) 1991-07-25

Family

ID=10669020

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1991/000018 Ceased WO1991010434A1 (fr) 1990-01-09 1991-01-07 Medicaments comprenant de la methylcellulose ou de l'hydroxyalkyle methylcellulose, et leur utilisation

Country Status (3)

Country Link
AU (1) AU7053791A (fr)
GB (1) GB9000459D0 (fr)
WO (1) WO1991010434A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0611567A4 (fr) * 1992-06-12 1996-10-23 Teijin Ltd Poudre ultra-fine pour inhalation et production de cette poudre.
WO2001052818A1 (fr) * 2000-01-19 2001-07-26 Pharmaceutical Discovery Corporation Formulations de poudre seche antihistaminique a administration nasale
WO2004005423A1 (fr) 2002-07-03 2004-01-15 Kao Corporation Inactivateur d'allergenes
US8133991B2 (en) 2002-07-03 2012-03-13 Kao Corporation Allergen inactivating agent

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2085692A1 (fr) * 1970-03-10 1971-12-31 Squibb & Sons Inc
EP0193372A2 (fr) * 1985-02-25 1986-09-03 Teijin Limited Composition pharmaceutique sous forme de poudre applicable par voie intranasale

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2085692A1 (fr) * 1970-03-10 1971-12-31 Squibb & Sons Inc
EP0193372A2 (fr) * 1985-02-25 1986-09-03 Teijin Limited Composition pharmaceutique sous forme de poudre applicable par voie intranasale

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts, vol. 99, no. 21, 21 November 1983, (Columbus, Ohio, US), see page 75 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0611567A4 (fr) * 1992-06-12 1996-10-23 Teijin Ltd Poudre ultra-fine pour inhalation et production de cette poudre.
US5972388A (en) * 1992-06-12 1999-10-26 Teijin Limited Ultrafine particle power for inhalation and method for production thereof
WO2001052818A1 (fr) * 2000-01-19 2001-07-26 Pharmaceutical Discovery Corporation Formulations de poudre seche antihistaminique a administration nasale
WO2004005423A1 (fr) 2002-07-03 2004-01-15 Kao Corporation Inactivateur d'allergenes
EP1550705A4 (fr) * 2002-07-03 2008-09-24 Kao Corp Inactivateur d'allergenes
US8133991B2 (en) 2002-07-03 2012-03-13 Kao Corporation Allergen inactivating agent

Also Published As

Publication number Publication date
AU7053791A (en) 1991-08-05
GB9000459D0 (en) 1990-03-07

Similar Documents

Publication Publication Date Title
US4953545A (en) Disposable respiratory medication dispersion chamber
JP4546699B2 (ja) スプレー装置
US5941241A (en) Method and device for organizing and coordinating the combined use of topical aerosols for the treatment of respiratory disorders
JP5283334B2 (ja) 経粘膜伝達用組成物材料
US4570630A (en) Medicament inhalation device
AU680874B2 (en) Inhalation device
US6561188B1 (en) Nasal breathing apparatus and methods
US20110308516A1 (en) Delivery device for a powder aerosol
ZA200700133B (en) Dry powder inhaler
CA2146954A1 (fr) Inhalateur active par la respiration
WO1995016482A1 (fr) Appareil d'inhalation par aerosol a plusieurs usages
DE69306379D1 (de) Inhalierbare arzneimittel
JPH02500172A (ja) 粉状薬剤施薬容器
JP2005508963A (ja) 喘息を治療するためのサルメテロールとフルチカゾンプロピオネートを含む医薬の組み合せ
WO1991010434A1 (fr) Medicaments comprenant de la methylcellulose ou de l'hydroxyalkyle methylcellulose, et leur utilisation
JPH05123398A (ja) 咽喉保護吸入剤並びに吸入器具
US9737550B2 (en) Treatment of congestion using steroids and adrenergics
US3156614A (en) Medicinal compositions and method for relieving cough
WO2007088425A2 (fr) dispositif inhalateur
JPH03143457A (ja) 揮発性医薬品を含む多孔性物質
CN209376756U (zh) 一种口罩
JPH0510815Y2 (fr)
TR202008382A1 (tr) İnhalatör
CN120093055A (zh) 一种可缓释药物的口罩及药物芯包
Newhouse et al. Conquering Asthma

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA JP KR NO US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase
122 Ep: pct application non-entry in european phase